Peer-reviewed articles, meta-analyses, conference presentations, book chapters and patents from the Marchand Institute for Minimally Invasive Surgery. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane RoB 2 tool — read how we run a review.
Search by title, author, journal, DOI or PMID, or filter by publication type and year. New work is announced through our publications RSS feed.
1,200+ citations · h-index 18 · i10-index 26 (Google Scholar, August 2026) · 65 PROSPERO registrations
Methodology · Research team · Clinical trials · Identifiers & preferred affiliation · Propose a collaboration
138 publications · Subscribe via RSS
- 13.
- 12.
- 11.
- 10.
- 9.
- 8.
- 7.
- 6.
- 5.
- 4.
- 3.
- 2.
- 1.
Citation Impact
Research published by the Marchand Institute is cited by other investigators in the medical literature. The citations below are references to our work in journals published by other groups. They are not Institute publications.
Cited in all three leading general medical journals
- New England Journal of Medicine. Gorelick DA. Cannabis-Related Disorders and Toxic Effects. N Engl J Med. 2023;389(24):2267-2275.
- JAMA. Hsu M, Shah A, Jordan A, Gold MS, Hill KP. Therapeutic Use of Cannabis and Cannabinoids: A Review. JAMA. 2026;335(4):345.
- The BMJ. Solmi M, De Toffol M, Kim JY, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348.
All three cite the same Institute paper: Marchand G, Masoud AT, Govindan M, et al. Birth outcomes of neonates exposed to marijuana in utero: a systematic review and meta-analysis. JAMA Network Open. 2022;5(1):e2145653.
Cited in national practice guidance
The Institute’s 2021 meta-analysis comparing salpingectomy with tubal ligation (Mills K, Marchand G, Sainz K, et al. Am J Obstet Gynecol. 2021;224(3):258-265.e4) was cited in the Canadian Medical Association Journal’s practice guidance on opportunistic salpingectomy for ovarian cancer risk reduction (CMAJ. 2024;196(22):E765). It appears there alongside Guideline No. 366 of the Society of Obstetricians and Gynaecologists of Canada and ACOG Committee Opinion No. 774, as one of six supporting sources and the only systematic review or meta-analysis among them. The same paper is cited in Endocrine Reviews (2025;46(5):736-759) in guidance on contraceptive selection for the endocrine patient.
Thirty-six citations in first-rank journals
As of August 2026, Institute research has been cited thirty-six times in journals of the first rank, across four groups:
- JAMA network. JAMA, JAMA Internal Medicine, JAMA Pediatrics, JAMA Health Forum, and JAMA Network Open, including the invited commentary that accompanied our 2022 meta-analysis.
- Lancet titles. The Lancet Public Health, The Lancet Global Health, The Lancet Regional Health – Americas, and eClinicalMedicine.
- Nature titles. Nature Reviews Immunology, Nature Reviews Microbiology, Nature Reviews Disease Primers, and Nature Communications. The Nature Reviews Disease Primers monograph on ovarian cancer cites work published by Dr. Marchand in 2012.
- Other leading journals. Pediatrics, CMAJ, the Medical Journal of Australia, Endocrine Reviews, Molecular Psychiatry, eBioMedicine, BMC Medicine, BMJ Global Health, Cellular & Molecular Immunology, and the Journal of General Internal Medicine.
Citation data compiled from PubMed, Europe PMC, Semantic Scholar and OpenCitations. Verified 28 August 2026.